NeoVanc has reached patient No. 50

18 Sep, 2017

We are proud to announce that our milestone of 50 patients has been reached.

Congratulations to all recruiting sites for this remarkable result!

The NeoVanc trial is part of of the NeoVanc project, funded by the European Commission under the FP7 programme. It aims at adapting an off-patent medicine to the specific need of paediatric populations: in specific to develop an optimal dosing and monitoring regimen for vancomycin use in preterm neonates and infants under 3 months of age in order to be able to register it for use in this age group with a PUMA.